Publications by authors named "Habte A Yimer"

Claim this Profile
Z
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Mazyar Shadman, John M Burke, Jennifer Cultrera, Habte A Yimer, Syed F Zafar

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Habte A Yimer

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter, Habte A Yimer

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer

Hematol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Habte A Yimer

Future Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Habte A Yimer

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien, Habte A Yimer

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Habte A Yimer

Lancet Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Habte A Yimer

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, Habte A Yimer

Haematologica· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Alexey V Danilov, Habte A Yimer, Michael A Boxer, John M Burke, Sunil Babu

Clin Lymphoma Myeloma Leuk· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
Jeff P Sharman, John M Burke, Habte A Yimer, Michael A Boxer, Sunil Babu

Leuk Lymphoma· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A Yimer, Stephen J Noga, Saulius Girnius, Christopher A Yasenchak

Clin Lymphoma Myeloma Leuk· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Habte Aragaw Yimer

Lancet Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Alok A Khorana, Gerald A Soff, Ajay K Kakkar, Saroj Vadhan-Raj, Hanno Riess, Habte A Yimer

N Engl J Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis